Biovest International, Inc. (BVTI.OB) Signs Distribution Agreement for Anti-Cancer Vaccine in Europe
Biovest International, Inc. develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA. Yesterday the company announced that it has executed a distribution agreement with IDIS Limited to exclusively supply BiovaxID®. IDIS is the world leader in the…